Introduction {#S1}
============

TGF-β was initially described in 1982 ([@B1]). It was already known to have bi-functional effects, as it can stimulate or inhibit growth of the same cell, depending on conditions ([@B2]). These initial reports have demonstrated the mysterious and important nature of TGF-β in physiology and pathology. More than 40 years later, our understanding of TGF-β signaling has greatly expanded and TGF-β is known as an important mediator in cancer progression. In this review, we provide insights into the mystery of the well-known phenomenon of "TGF-β paradox," mainly based on our own experience, along with the literature information. It should be pointed out that this report is limited to few salient aspects of TGF-β signaling relevant to the present discussion. For a more comprehensive description of TGF-β signaling, please refer to our recent review ([@B3]).

Biology of TGF-β Signaling {#S2}
==========================

There are three known mammalian isoforms of TGF-β (TGF-β1, -β2, and -β3) with significant structural and functional similarity ([@B4]). The biological effect of TGF-β is mediated through type I and type II receptors (TBRI and TBRII) ([@B5]). The canonical downstream events involve the activation of Smad pathways ([@B6]). TGF-β first binds to TBRII, which recruits and activates TBRI ([@B5], [@B7]). The latter then activates Smad2/3. The activated Smad2/3 combines with Smad4 and migrates to the nucleus to regulate transcription ([@B8]). In addition to the Smad pathway, TGF-β also signals through a number of non-canonical pathways, including m-TOR, RhoA, Ras, MAPK, PI3K/AKT, PP2A/p70s6K, and JNK ([@B9]). The relative importance and interplay of these pathways of TGF-β signaling is still under investigation ([@B10], [@B11]). In this review, we will limit our discussion to TGF-β-mediated Smad and Erk activation.

TGF-β Paradox {#S3}
=============

TGF-β is known to inhibit cell cycle in benign cells but promote progression and metastasis in cancer cells ([@B3], [@B12]), a phenomenon known as TGF-β paradox ([@B13]). Although there are numerous articles with different approaches tackling this topic, to date, a logical explanation leading to TGF-β paradox remains elusive and is accepted as a scientific mystery ([@B3], [@B13]--[@B15]). In this study, we searched the recent literature, along with our own experience, in an attempt to explain this mystery.

Mystery of TGF-β Paradox 1 {#S4}
==========================

Differential activation of Erk between benign and cancer cells {#S4-1}
--------------------------------------------------------------

It is well-known that TGF-β is able to activate Erk in cancer cells ([@B16]--[@B18]) and inactivate Erk in non-cancer cells ([@B19]). However, a direct link of TGF-β-mediated differential activation of Erk between cancer and non-cancer cells in the same cell system has not been reported until our recent report ([@B20]), where we treated benign cells with a low concentration of TGF-β (0.1 ηg/ml), which led to Erk activation; while the treatment of the same cells with a high concentration of TGF-β (10 ηg/ml) resulted in Erk inactivation. Activated Erk is a key regulator for cell proliferation. Consistent with this finding, we have observed cell proliferation in benign cells with a low dose of TGF-β but growth arrest with a high dose in benign stromal cells ([@B21]) as well as in benign epithelial cells ([@B17]). The use of different dosages of TGF-β in these studies is critical as they bring out the interesting phenomenon of differential responses to TGF-β stimulation. It should be pointed out that cancer cells in the early stage of carcinogenesis retain some of the features of benign cells in which they can be inhibited by TGF-β ([@B22], [@B23]). However, in advanced cancer cells, treatment with TGF-β would result in Erk activation and cell proliferation ([@B16], [@B17], [@B21], [@B24]).

The above explanation to TGF-β paradox is summarized in Figure [1](#F1){ref-type="fig"}. An important point is that, in contrast to the traditional concept of TGF-β paradox ([@B13], [@B17]), TGF-β treatment in benign cells does not always result in growth arrest. Figure [1](#F1){ref-type="fig"} indicates that under normal physiological conditions, cellular activities are carefully monitored by TGF-β. Differential Erk activation seems to play a central role in this regulation. When TGF-β level in the local environment is low, cells will activate Erk and induce TGF-β expression ([@B20]). On the other hand, when the local concentration of TGF-β is more than sufficient, cells have a mechanism to shut off Erk activation, thus, prevent further expression of TGF-β.

![**A proposed mechanism to explain the TGF-β paradox between benign and tumor cells**. First, in benign cells, a low dose of TGF-β in the microenvironment will result in Erk activation and cell proliferation. At the same time, there will be an auto-induction of TGF-β, which will create a high dose of TGF-β in the microenvironment and lead to growth arrest. Therefore, the level of TGF-β is regulated via a negative feedback loop. On the other hand, in cancer cells, Erk will be activated regardless of the level of TGF-β in the microenvironment. The activated Erk is a master regulator of tumor progression and metastasis. It will also auto-induce more TGF-β, which will create a positive feedback of TGF-β signaling in tumor progression. The level of TGF-β is regulated via a positive feedback loop.](fonc-04-00094-g001){#F1}

It is important to note that Erk activation or inactivation by TGF-β in benign cells is not a case of all-or-none phenomenon. In order to demonstrate the gradual changes in Erk or Smad activation in benign cells, multiple doses of TGF-β at different cell density must be employed as described by Clarke et al. ([@B25]). Indeed, they demonstrated a linear increment of Smad activation within a wide range of available TGF-β per cell in mink lung epithelial cells ([@B25]). In an attempt to validate the same linear relationship exists between TGF-β dosage and Erk inactivation, we repeated the same experiment performed by Clarke et al. ([@B25]) by using a different set of benign epithelial cells (RWPE1 and BPH1). Indeed, a linear Erk inactivation was demonstrated (Figure [2](#F2){ref-type="fig"}). This phenomenon is applied only to benign cells or early-stage cancer cells, as in advanced cancer cells, there will be no such linear relationship in Smad activation and Erk inactivation upon TGF-β stimulation. In advanced cancer cells, Erk is constantly in an activated state ([@B17], [@B20]) and Smad activation is suppressed, regardless of the level of TGF-β employed. This finding has an important implication in TGF-β paradox, that is, in benign cells or early stage cancer cells, TGF-β offers a mechanism for homeostasis; whereas in advanced cancer cells, it promotes tumor progression (Figure [1](#F1){ref-type="fig"}).

![**BPH1 and RWPE1 are immortalized benign prostate epithelial cells**. The cells were treated with 12 different doses of TGF-β1 for 5 min and probed for p-Erk and total Erk (T-Erk) by western blot analysis. A linear relationship between the cellular response (relative value of p-Erk corrected for GAPDH in natural logarithm) and the available level of TGF-β molecules per cell (in natural logarithm) was plotted according to the method described by Clarke et al. ([@B25]). In response to a low number of TGF-β1 molecules, there is an increase in the level of Erk. As the number of TGF-β1 molecules increases, there is a linear decline in the relative level of p-Erk in BHP1 cells \[**(A--D)**; *r* = −0.86, *p* \< 0.05\]. A similar phenomenon was observed on RWPE1 cells \[**(E--H)**; *r* = −0.77, *p* \< 0.05\]. There is no change in the amount of T-Erk. Unlike benign cells, malignant cells (DU145 and PC3) always showed an activation of Erk regardless of the dosage of TGF-β1 used in the experiment (data not shown).](fonc-04-00094-g002){#F2}

Mystery of TGF-β Paradox 2 {#S5}
==========================

Differential recruitment of PP2A-B56α by activated TBRI {#S5-2}
-------------------------------------------------------

The observation of a differentially activated Erk between benign and cancer cells offers an explanation to the mystery of TGF-β paradox (Figure [1](#F1){ref-type="fig"}). The question remains as how the differentially activated Erk is regulated? Our recent observation has identified a key player, PP2A-B56α (subunit B56α of protein phosphatase 2A), which plays a pivotal role in the regulation of differentially activated Erk between benign and cancer cells upon TGF-β engagement ([@B20]). PP2A is a known tumor suppressor ([@B26], [@B27]) and is involved in a broad range of cellular processes, including signal transduction, transcriptional regulation, and control of the cell cycle. The PP2A holoenzyme is a heterotrimer that consists of a core dimer, which has scaffold (A) and catalytic (C) subunits that associate with a variety of regulatory (B) subunits. PP2A-A brings the PP2A-B and -C subunits together. PP2A-C performs the enzymatic reaction, while PP2A-B is responsible to direct the cellular localization and site specificity. The B subunits have been divided into gene families named B (or PR55), B′ (or B56 or PR61), and B″ (or PR72) ([@B28]). These B subunits determine the substrate specificity as well as the spatial and temporal functions of PP2A ([@B28]). The B56 family consists of B56α, β, γ, δ, and ε, generating at least eight isoforms ([@B28]).

TGF-β is known to activate PP2A-Bα in benign cells ([@B26]). Only recently, we and others have observed a differential recruitment of PP2A-B56α (but not other PP2As) by the activated TBRI in benign and cancer cells ([@B20], [@B29]). Upon TGF-β treatment in benign cells, TBRII is able to recruit and activate TBRI ([@B5], [@B7]). We found that PP2A-B56α was able to be co-precipitated with the activated TBRI in benign cells in large quantities, leading to inactivation of Erk ([@B20]). But in cancer cells, since there is a limited available amount of activated TBRI ([@B30]), a limited or no PP2A-B56α was able to be co-precipitated with TBRI, resulting in activation of Erk ([@B20], [@B31]). PP2A is ubiquitously synthesized but is specifically recruited and activated by the activated TBRI to function as an inhibitor to Erk activation ([@B20], [@B31]). This observation was independently validated by others using a different cell system ([@B29]).

A key event in TGF-β paradox is the recruitment of PP2A-B56α by the activated TBRI ([@B20], [@B29]). In benign cells, PP2A-B56α is recruited by the activated TBRI, which is dependent on the dosage of TGF-β used to stimulate the target cells. At a high dose of TGF-β, a sufficient quantity of PP2A-B56α is recruited by the activated TBRI, resulting in an inhibition of Erk activation; while at a low dose of TGF-β, due to a limited quantity of TBRI being activated, there will be a limited quantity of PP2A-B56α to be recruited resulting in Erk activation. In the context of advanced cancer cells, due to a severely down-regulated TBRI ([@B30]), recruitment of PP2A-B56α is always compromised regardless of the dosage of TGF-β employed, resulting in an elevated activation of Erk ([@B20]). This PP2A-B56α-mediated differential Erk activation between benign and malignant cells offers an answer to the mystery of TGF-β paradox.

Mystery of TGF-β Paradox 3 {#S6}
==========================

Differential suppression of TBRs and auto-induction of TGF-β {#S6-3}
------------------------------------------------------------

Finally, we ask what are the triggering factor and the consequence of the observed differentiated Erk activation in TGF-β paradox. We conclude that the downregulation of TBRs is the triggering factor and the over expression of TGF-β is the consequence of the TGF-β paradox ([@B15]). Both events have important implications.

It is well-known that, in advanced cancer cells, TGF-β mediates downregulation of TBRs and auto-induction of TGF-β in cancer cells but not in benign cells ([@B31]--[@B34]). Since the activated Erk is a master regulator for tumor progression ([@B16]), it is responsible for a host of oncogenic signaling events including NF-κB activation, which up-regulates DNA methyltransferases (DNMTs) ([@B35]). Targets of DNMTs promoter methylation in many tumor suppressor genes are TBRs ([@B34], [@B35]). A search of the literature has revealed that downregulation of TBRs is an early event of carcinogenesis for all types of cancer ([@B36]). The biological consequence of a downregulated TBR will be an attenuate Smad2/3 activation and an elevated Erk1/2 activation in advanced cancer cells. The availability of TBRs dictates the relative levels of activated Erk1/2 and inactivated Smad2/3, thus determines the fate of the TGF-β paradox ([@B25], [@B37], [@B38]). It follows that any condition that results in downregulation of functional TBRs, such as inflammation ([@B39], [@B40]), Ras activation ([@B41], [@B42]), and loss-of-function mutations in TBRs ([@B43]--[@B45]), will be predisposed to development and progression of cancer.

TGF-β overproduction is also an universal event in cancer cells and is a poor prognostic marker ([@B20], [@B35], [@B46]--[@B49]). The mechanism, although which TGF-β regulates its own production, is different between benign and cancer cells. Under the normal physiological conditions, the level of TGF-β is tightly regulated within the microenvironment through a negative feedback loop (Figure [1](#F1){ref-type="fig"}) to maintain a relatively constant level of TGF-β. Too little or too much TGF-β will have an unfavorable consequence ([@B36], [@B50], [@B51]). However, this principle does not apply to cancer. Cancer cells, especially the advanced cases, are capable of evading the immune surveillance program due to the well-known phenomenon of auto-induction of TGF-β by cancer cells ([@B20]), resulting in an elevated TGF-β in the microenvironment through a positive feedback loop ([@B52]). As a result, there is an accumulation of TGF-β in the microenvironment, which further promotes tumor progression ([@B20], [@B35], [@B48]). Therefore, with regard to TGF-β signaling, a characteristic feature of cancer cells, as opposed to the benign cells, is suppressed TBRs (the cause) and an elevated TGF-β (the effect). This feature applies to all cancer cells and can be used as a biomarker for prediction of aggressiveness of the cancer ([@B17], [@B35]).

Conclusion {#S7}
==========

Positive feedback of TGF-β signaling in tumor progression {#S7-4}
---------------------------------------------------------

In summary, this review indicates that a differential Erk activation plays a central role in deciding whether the target cell will undergo growth arrest or proliferation in response to TGF-β. In addition, the description of the conventional concept of "TGF-β Paradox" ([@B12]--[@B15]) may require a slight modification. First, the term TGF-β paradox does not imply that TGF-β inhibits cell cycle in benign cells. As indicated in this review, benign cells can also be stimulated by TGF-β to undergo proliferation, if the dose of TGF-β is low. Furthermore, cancer cells can be inhibited by TGF-β, especially in the early stages of carcinogenesis, if a sufficient level of TBRs can be activated (Figure [1](#F1){ref-type="fig"}). Therefore, we conclude that a more appropriate interpretation for TGF-β paradox should be that TGF-β mediates cellular homeostasis in benign cells but promotes tumor progression and metastasis in advanced cancer cells. Second, the term of TGF-β paradox does not imply an all-or-none phenomenon ([@B13], [@B17]). In fact, the changes in target cells in the level of Erk1/2 activation or Smad2/3 inactivation mediated by TGF-β are gradual depending on the relative levels of TGF-β present available per cell in the local microenvironment \[Ref. ([@B25]), Figure [2](#F2){ref-type="fig"}\]. Also, TGF-β-mediated changes in cell proliferation or growth arrest takes place in a gradual manner depending on the dosage of TGF-β employed ([@B20], [@B35]).

The consequence of Erk activation in cancer cells can result in a continuous TGF-β auto-induction via a positive feedback loop (Figure [1](#F1){ref-type="fig"}). This continuous production of TGF-β in the tumor microenvironment will further stimulate tumor progression and metastasis resulting in the manifestation of the development of a more aggressive tumor progression. The implications of this positive feedback of TGF-β signaling in tumor progression are at least twofold. First, this knowledge can be used for the prediction of cancer outcome in that TGF-β content in the tumor can be used to predict whether or not the tumor in question is indolent or aggressive ([@B17], [@B35]). Second, due to the knowledge that TGF-β in the tumor microenvironment is highly immune-suppressive ([@B53]), it will be important to render the cytotoxic cells insensitive to TGF-β in cancer immunotherapy ([@B54]).
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